Suppr超能文献

来氟米特:系统性红斑狼疮的朋友还是敌人?

Leflunomide: friend or foe for systemic lupus erythematosus?

机构信息

Department of Pharmacy, Binhu Hospital, The First People's Hospital of Hefei City, Lakeshore New District, Hefei 230001, Anhui, China.

出版信息

Rheumatol Int. 2013 Feb;33(2):273-6. doi: 10.1007/s00296-012-2508-z. Epub 2012 Sep 8.

Abstract

Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.

摘要

来氟米特是一种新型免疫抑制剂,已成功地应用于类风湿关节炎的治疗,并随后在动物模型和系统性红斑狼疮(SLE)患者中取得疗效。然而,其应用也与涉及血液、肝脏、免疫、皮肤和呼吸系统的严重不良反应相关。在目前的综述中,我们尝试描述该药在 SLE 治疗中的两面性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验